| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 408 | 444 | 398 | 435 | 459 | 475 | 445 | 447 | 545 | 452 | 604 | 554 | 619 | 613 | 605 | 627 | 786 | 811 | 796 | 767 | 902 | 889 | 852 | 878 | 1,010 | 1,011 | 972 | 964 |
| Expenses | 326 | 354 | 304 | 353 | 350 | 356 | 339 | 362 | 367 | 334 | 377 | 405 | 442 | 466 | 473 | 500 | 612 | 625 | 618 | 599 | 664 | 638 | 621 | 664 | 724 | 730 | 709 | 723 |
| EBITDA | 82 | 90 | 94 | 81 | 109 | 119 | 106 | 85 | 178 | 119 | 227 | 149 | 177 | 146 | 133 | 127 | 174 | 186 | 178 | 168 | 238 | 251 | 231 | 215 | 286 | 281 | 263 | 241 |
| Operating Profit % | 20 % | 19 % | 20 % | 16 % | 22 % | 22 % | 21 % | 18 % | 30 % | 25 % | 31 % | 23 % | 27 % | 21 % | 21 % | 20 % | 22 % | 23 % | 22 % | 21 % | 26 % | 28 % | 26 % | 23 % | 28 % | 27 % | 26 % | 24 % |
| Depreciation | 15 | 15 | 15 | 12 | 16 | 16 | 17 | 17 | 17 | 18 | 17 | 17 | 18 | 16 | 17 | 22 | 26 | 28 | 28 | 32 | 31 | 32 | 34 | 41 | 41 | 42 | 42 | 46 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 8 | 8 | 14 | 12 | 10 | 13 | 9 | 6 | 2 | 3 | 2 |
| Profit Before Tax | 66 | 75 | 78 | 68 | 92 | 102 | 88 | 67 | 157 | 99 | 209 | 132 | 158 | 129 | 114 | 103 | 142 | 150 | 141 | 123 | 194 | 209 | 184 | 165 | 240 | 237 | 218 | 193 |
| Tax | 21 | 23 | 28 | 22 | 30 | 8 | 22 | 17 | 38 | 25 | 54 | 31 | 39 | 32 | 30 | 18 | 37 | 39 | 35 | 35 | 52 | 58 | 50 | 38 | 63 | 62 | 56 | 47 |
| Net Profit | 46 | 52 | 50 | 47 | 62 | 94 | 66 | 50 | 120 | 74 | 154 | 101 | 119 | 98 | 84 | 85 | 105 | 111 | 106 | 88 | 142 | 151 | 134 | 126 | 177 | 175 | 163 | 146 |
| EPS in ₹ | 5.46 | 6.14 | 6.07 | 5.68 | 7.73 | 11.67 | 8.26 | 6.30 | 15.45 | 9.55 | 19.94 | 13.02 | 15.38 | 12.65 | 10.85 | 10.98 | 13.59 | 14.37 | 13.72 | 11.33 | 9.20 | 9.72 | 8.62 | 8.22 | 11.39 | 11.24 | 10.46 | 9.36 |
J B Chemicals and Pharmaceuticals
1,652.90
+15.00
(0.92%)
Market Cap
25,794.98 Cr
EPS
42.45
PE Ratio
40.02
Dividend Yield
0.94 %
Industry
Healthcare52 Week High
2,030.00
52 Week Low
1,385.75
PB Ratio
7.45
Debt to Equity
0.06
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,726.00 | #1 4,14,125.22 | 35.23 | #1 54,729.00 | 12.06 | #1 10,980 | -18.99 | 52.11 | |
6,757.00 | 1,79,377.12 | 82.19 | 9,360.00 | 0.89 | 2,117 | 23.05 | 53.82 | |
1,491.80 | 1,20,493.85 | 23.31 | 28,409.50 | 7.12 | 5,291 | 30.28 | 44.66 | |
3,445.00 | 1,16,594.45 | 60.20 | 11,539.40 | 11.59 | 1,911 | 10.91 | 62.33 | |
2,649.50 | 1,09,352.48 | 56.09 | 12,207.40 | 19.57 | 1,925 | -10.91 | 76.79 | |
1,255.20 | 1,04,755.36 | #1 18.82 | 33,741.20 | 12.36 | 5,725 | 21.14 | 38.64 | |
973.05 | 97,911.60 | 20.87 | 22,573.80 | 13.82 | 3,977 | -0.19 | 49.02 | |
1,959.00 | 89,466.64 | 26.79 | 22,192.10 | #1 19.94 | 3,024 | #1 112.49 | 44.79 | |
34,315.00 | 72,916.98 | 51.66 | 6,409.15 | 10.80 | 1,417 | 27.83 | 59.37 | |
1,155.40 | 67,105.82 | 19.14 | 31,378.10 | 17.55 | 3,366 | -0.50 | 48.47 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
11.46 %
Net Income Growth
34.78 %
Cash Flow Change
12.72 %
ROE
14.34 %
ROCE
29.17 %
EBITDA Margin (Avg.)
18.76 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,821 | 2,238 | 2,607 | 3,554 | 3,994 | 4,274 |
| Fixed Assets | 329 | 440 | 679 | 640 | 621 | 651 | 634 | 1,277 | 1,901 | 2,004 | 1,968 |
| Current Assets | 901 | 816 | 795 | 1,047 | 1,051 | 1,073 | 1,553 | 1,253 | 1,528 | 1,853 | 1,923 |
| Capital Work in Progress | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 | 63 |
| Investments | 367 | 479 | 411 | 434 | 457 | 403 | 678 | 13 | 206 | 388 | 345 |
| Other Assets | 737 | 594 | 580 | 674 | 699 | 750 | 901 | 1,299 | 1,392 | 1,525 | 1,897 |
| Total Liabilities | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,821 | 2,238 | 2,607 | 3,554 | 3,994 | 4,274 |
| Current Liabilities | 460 | 431 | 281 | 275 | 244 | 313 | 345 | 384 | 554 | 868 | 632 |
| Non Current Liabilities | 33 | 31 | 27 | 46 | 65 | 69 | 79 | 85 | 519 | 203 | 208 |
| Total Equity | 995 | 1,186 | 1,366 | 1,444 | 1,483 | 1,438 | 1,813 | 2,139 | 2,480 | 2,923 | 3,433 |
| Reserve & Surplus | 978 | 1,167 | 1,347 | 1,425 | 1,464 | 1,420 | 1,794 | 2,119 | 2,465 | 2,908 | 3,418 |
| Share Capital | 17 | 17 | 17 | 17 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 13 | 15 | -28 | 43 | 11 | -6 | -3 | 34 | 20 | 11 | 27 |
| Investing Activities | -112 | -26 | -45 | -21 | -28 | 24 | -231 | 2 | -962 | -404 | -296 |
| Operating Activities | 127 | 140 | 201 | 123 | 194 | 276 | 315 | 170 | 626 | 801 | 903 |
| Financing Activities | -1 | -100 | -184 | -60 | -156 | -306 | -87 | -138 | 357 | -386 | -580 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 55.91 % | 55.91 % | 55.91 % | 54.00 % | 54.00 % | 54.00 % | 53.96 % | 53.95 % | 53.93 % | 53.91 % | 53.86 % | 53.83 % | 53.78 % | 53.77 % | 53.74 % | 53.66 % | 47.84 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.05 % | 0.00 % | 11.06 % | 12.17 % | 13.63 % | 14.64 % | 18.30 % |
| DIIs | 12.41 % | 12.32 % | 14.76 % | 16.03 % | 16.67 % | 17.52 % | 18.08 % | 18.54 % | 19.08 % | 18.65 % | 18.58 % | 17.97 % | 18.38 % | 17.62 % | 16.81 % | 16.41 % | 18.72 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % |
| Public / Retail | 20.50 % | 19.69 % | 17.64 % | 18.38 % | 17.87 % | 17.37 % | 16.94 % | 16.70 % | 15.98 % | 15.66 % | 15.34 % | 15.17 % | 14.69 % | 14.38 % | 13.87 % | 13.42 % | 13.28 % |
| Others | 11.18 % | 12.08 % | 11.70 % | 11.58 % | 11.47 % | 11.10 % | 11.02 % | 10.81 % | 11.00 % | 11.79 % | 2.17 % | 13.03 % | 2.09 % | 2.05 % | 1.94 % | 1.87 % | 1.86 % |
| No of Share Holders | 0 | 65,715 | 70,740 | 71,788 | 64,861 | 61,314 | 60,268 | 58,629 | 56,633 | 55,965 | 60,817 | 63,230 | 63,892 | 66,953 | 62,743 | 62,081 | 63,948 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 5 | 1 | 2 | 5 | 11 | 16.5 | 16.5 | 17.75 | 12.25 | 15.5 |
| Dividend Yield (%) | 2.89 | 0.64 | 1.1 | 1.96 | 1.75 | 2.1 | 1.67 | 1.08 | 0.75 | 0.95 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 06 Aug 2025 |  Annual General Meeting | NA | 06 Aug 2025 | 1,612.55 | 1,639.85 |
| 30 Jul 2025 |  Dividend | ₹ 7.00 /share | 30 Jul 2025 | 1,579.85 | 1,639.85 |
| 14 May 2025 |  Quarterly Result Announcement | NA | 14 May 2025 | 1,658.70 | 1,579.85 |
| 08 Feb 2025 | Dividend | ₹ 8.50 /share | 07 Feb 2025 | 1,714.10 | 1,673.75 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,805.05 | 1,714.10 |
| 06 Nov 2024 | Quarterly Result Announcement | NA | 06 Nov 2024 | 1,895.75 | 1,852.00 |
| 21 Aug 2024 | Annual General Meeting | NA | 21 Aug 2024 | 1,788.80 | 1,942.60 |
| 14 Aug 2024 | Dividend | ₹ 6.75 /share | 14 Aug 2024 | 1,832.55 | 1,941.60 |
| 16 Feb 2024 | Dividend | ₹ 5.50 /share | 16 Feb 2024 | 1,708.40 | 1,664.30 |
| 24 May 2023 |  Split | 1:2 | 18 Sept 2023 | 976.00 | 976.00 |
| 17 Aug 2023 | Dividend | ₹ 9.25 /share | 17 Aug 2023 | 976.00 | 1,315.08 |
| 18 Feb 2023 | Dividend | ₹ 8.50 /share | 17 Feb 2023 | 1,008.50 | 982.73 |
| 17 Aug 2022 | Dividend | ₹ 8.00 /share | 12 Aug 2022 | 785.18 | 931.68 |
| 24 Feb 2022 | Dividend | ₹ 8.50 /share | 23 Feb 2022 | 852.88 | 804.93 |
| 02 Sept 2021 | Dividend | ₹ 8.00 /share | 01 Sept 2021 | 770.03 | 850.15 |
| 22 Feb 2021 | Dividend | ₹ 8.50 /share | 18 Feb 2021 | 520.90 | 555.25 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 days ago
2 days agoDraft Letter of Offer3 days ago
3 days agoBusiness Responsibility and Sustainability Reporting (BRSR)3 days ago
3 days agoIntimation Of Record Date3 days ago
3 days agoReg. 34 (1) Annual Report.3 days ago
3 days agoNotice Of Annual General Meeting3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Change in Directorate4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication10 days ago
10 days agoUpdates on Open Offer10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Investor PresentationJun 30, 2025
Jun 30, 2025Public AnnouncementJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Public Announcement-Open OfferJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 29, 2025
Jun 29, 2025Announcement under Regulation 30 (LODR)-Change in Registered Office AddressJun 29, 2025
Jun 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 29, 2025
Jun 29, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJun 28, 2025
Jun 28, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025ANDA Approval By US FDAJun 26, 2025
Jun 26, 2025ANDA Approval By US FDAJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 11, 2025
Jun 11, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 25, 2025
May 25, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2025
May 15, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AMay 14, 2025
May 14, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 14, 2025
May 14, 2025Appointment Of Secretarial AuditorMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 14, 2025
May 14, 2025Corporate Action-Board approves DividendMay 14, 2025
May 14, 2025Audited Standalone & Consolidated Financial Results For The Year Ended On March 31 2025May 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
May 14, 2025Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For The Year Ended On March 31 2025 Accompanied By Auditors Report.May 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 23, 2025
Apr 23, 2025Board Meeting Intimation for (I) Consideration And Approval Of The Audited Financial Results For The Quarter And Year Ended On March 31 2025; And
(Ii) Consideration And Recommendation Of Dividend On Equity Shares Of The Company If Any Subject To ApprovaApr 22, 2025
Apr 22, 2025ANDA Approval By US FDAApr 18, 2025
Apr 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Apr 14, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 11, 2025
Apr 11, 2025Noting Of Cautionary Letter Received From The ExchangesApr 11, 2025
Apr 11, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Apr 01, 2025
Apr 01, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 29, 2025
Mar 29, 2025Technical Indicators
RSI(14)
Neutral 43.92
ATR(14)
Less Volatile 41.77
STOCH(9,6)
Oversold 15.67
STOCH RSI(14)
Oversold 7.36
MACD(12,26)
Bearish -11.35
ADX(14)
Weak Trend 22.37
UO(9)
Bearish 47.58
ROC(12)
Downtrend And Accelerating -6.53
WillR(14)
Oversold -85.62
Mutual Fund Holdings
Union Small Cap Fund Direct-Growth 
Bandhan Small Cap Fund Direct-Growth 
LIC MF Focused Fund Direct - Growth 
Canara Robeco ELSS Tax Saver Direct- Growth 
Baroda BNP Paribas Health and Wellness Fund Direct-Growth 
Axis Equity Savings Fund Direct-Growth 
Aditya Birla Sun Life Small Cap Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
Motilal Oswal Quant Fund Direct-Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
Groww Multicap Fund Direct-Growth 
WhiteOak Capital Special Opportunities Fund Direct - Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
Tata Nifty MidSmall Healthcare Index Fund Direct - Growth 
Mirae Asset Small Cap Fund Direct-Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth About J B Chemicals and Pharmaceuticals
J.B. Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1976. It manufactures and markets a range of pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. The company specializes in gastroenterology, hypertension, and dermatology, with additional focus on nephrology, respiratory, virology, diabetes, and nicotine replacement therapy. Key brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. The company has manufacturing facilities in various locations in India and maintains a direct presence in Russia and South Africa, with distributor relationships in the US and other international markets. In 2020, Tau Investment Holdings Pte. Ltd., an affiliate of KKR, acquired a controlling stake in the company. J.B. Chemicals & Pharmaceuticals continues to expand its product portfolio through new launches and acquisitions in various therapeutic segments.
Website
Chairperson NameArun Duggal
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
